Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRYO-CELL (CCEL) -- Ignore unavailable to you. Want to Upgrade?

To: GOLDFINGER who wrote (23)	11/29/1999 12:22:00 PM
From: CUBBY	Respond to of 53

CRYO-CELL Launches European Expansion Program CLEARWATER, Fla., Nov. 29 /PRNewswire/ -- CRYO-CELL International, Inc. (Nasdaq: CCEL), the Company which pioneered commercial cryopreservation of separated umbilical cord blood stem cells, is expanding its operations to Continental Europe. Daniel D. Richard, Chairman and Chief Executive Officer of CRYO-CELL, announced today that a Letter of Intent has been signed with the Managing Director of CRYO-CELL Holdings (a corporation in the process of being formed). CRYO-CELL Holdings will have the exclusive rights to market CRYO-CELL's services throughout Continental Europe. Processing and laboratory facilities will be set up in a number of countries. The first group will be CRYO-CELL Belgium in Brussels, CRYO-CELL Netherlands in Amsterdam and CRYO-CELL Switzerland in Geneva. For the marketing rights in Europe, CRYO-CELL is to receive a guaranteed payment of $1.4 million. An initial deposit of $100,000 has been paid to CRYO-CELL. The scheduled payments of the remaining $1,300,000 will be completed within one year of signing the formal agreement. In addition to the $1,400,000, CRYO-CELL is to receive an on-going percentage of all net revenues from the processing and accumulating fees for storage of umbilical cord blood, sperm, tumor tissue, stem cells and all related cellular preservation and marketing activities. In order to stimulate rapid growth in Europe, CRYO-CELL is making available to the CRYO-CELL European participants options to purchase 300,000 shares of the Company's common stock. The exercise price is $8.00 per share for the first 100,000 shares, $10.00 for the second 100,000 shares and $12.00 for the final 100,000 shares. All shares must be held for a minimum of one year after exercise. According to Mr. Richard, CRYO-CELL will have no overseas operational or marketing expenses. The Company will provide technical support and use its Web site at www.cryo-cell.com to attract inquiries from firms or individuals interested in becoming a part of CRYO-CELL's European expansion program. All inquires will be directed to CRYO-CELL Holdings Corp. A number of analysts and investors have recently visited CRYO-CELL's headquarters and state-of-the-art laboratory in Clearwater, Florida. Articles written in Dutch and French were published in Europe, which resulted in nearly 1,000,000 shares of CRYO-CELL stock being purchased by overseas investors. Mr. Richard stated, "The Company has also been informed that its stock is now being traded on a German Stock Exchange. This has had a positive impact on our company's market capitalization." Michael P. Isenberg, Assistant to the Chief Executive Officer, was responsible for initiating the European interest in CRYO-CELL. According to Mr. Isenberg, "The Company's overseas expansion is quite timely in light of Nasdaq's announced intention to commence stock trading in Europe next year. This will continue the ever increasing awareness of CRYO-CELL's growth by the European investment community." CRYO-CELL is a publicly traded company. Its common stock trades on The Nasdaq Stock Market(R) under the symbol ... C C E L Forward-Looking Statement Statements wherein the terms "believes," "intends," or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. SOURCE CRYO-CELL International, Inc. /CONTACT: Sharon Will of Saggi Capital Corp., 212-572-0762, or fax, 212-572-0764, for CRYO-CELL/ /Web site: cryo-cell.com /

To: GOLDFINGER who wrote (23)	12/2/1999 1:16:00 PM
From: CUBBY	Read Replies (2) \| Respond to of 53

CRYO-CELL Completes Financing Programs In Excess Of $1,800,000 CLEARWATER, Fla., Dec. 2 /PRNewswire/ -- Gerald F. Maass, Executive Vice President and General Manager of CRYO-CELL International, Inc. (Nasdaq: CCEL) announced today that the Company has concluded several financing transactions valued in excess of $1,800,000. Through a private placement offering, the Company has concluded the sale of 250,000 shares of its restricted common stock resulting in gross proceeds of $1,100,000 in cash. In separate transactions, the Company received $264,000 from the exercise of stock options and the private sale of its restricted common stock. The Company anticipates that, with its stock recently trading at an all-time high, other stock option contracts will be exercised providing additional cash. CRYO-CELL also received $50,000 in deposits for the purchase of a partial State Revenue Sharing Agreement. The agreement has a $500,000 value to the Company; the balance of $450,000 will be paid no later than the end of fiscal second quarter, 2000. The above amounts do not include the $1,300,000 expected during the next year from the sale of CRYO-CELL's European expansion partnership rights. Daniel D. Richard, Chairman and Chief Executive Officer, commented, "We are delighted to conclude our fiscal year with such a strong cash position on our balance sheet. This is especially significant because we are debt-free and expect to achieve profitability next year." CRYO-CELL recently celebrated its 10-year anniversary and is the pioneer of commercial storage of separated umbilical cord blood stem cells. "1999 has been a year of significant growth in the sale of the Company's U-Cord(TM) preservation program," commented Mr. Maass. "The Company is well positioned for the next millennium due to the ramp up of sales, our cash position and our recently announced European expansion program." CRYO-CELL is a publicly traded company. Its common stock trades on The Nasdaq Stock Market(R) under the symbol...C C E L Forward-Looking Statement Statements wherein the terms "believes," "intends," or "expects" as used are intended to reflect "forward looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward looking statements or paragraphs. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. SOURCE CRYO-CELL International, Inc. /CONTACT: Sharon Will of Saggi Capital Corp., 212-572-0762, or fax, 212-572-0764, for CRYO-CELL International, Inc./ /Web site: cryo-cell.com